Objective Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations
beginning at week 2 in biological-naïve patients with PsA. Methods Patients were …

Background The efficacy and safety of apremilast were assessed in patients with psoriatic
arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3) …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA).
Real-world evidence on the efficacy and safety of apremilast in clinical practice is limited …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Abstract Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The
objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Objectives The PALACE 4 trial evaluated apremilast monotherapy in patients with active
PsA who were DMARD-naive. Methods Eligible patients were randomized (1: 1: 1) to …

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small
molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic …